rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2001-464rsp-602Research ArticleСтатьиArticlesНОВЫЕ ПОДХОДЫ К АНАЛИЗУ ПАТОГЕНЕЗА И ПАТОГЕНЕТИЧЕСКОЙ ТЕРАПИИ РЕВМАТОИДНОГО АРТРИТАNЕW APPROACHES ТО ANALYSE OF PATHOGENESIS AND PATHOGENETIC THIRAPY OF RHEUMATOID ARTHRITISСигидинЯ. А.SigidinYa A-LoukinaG. V.LoukinaG. V.-200115102001395№5 (2001)411Copyright © Сигидин Я.А., Loukina G.V., 20012001Сигидин Я.А., Loukina G.V.Sigidin Y.A., Loukina G.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/602References<div><p>Гусев Д.Е. Влияние глюкокортикостероидов на прогрессирование ревматоидного артрита. Автореферат канд. дисс. М., 1997,29.</p><p>Гусев Д.Е. Сигидин Я.А. К характеристике влияния кортикостероидов на деструкцию суставов при ревматоидном артрите. Клин, ревматол., 1996. 1, 29-32.</p><p>Лукина Г.В., Сигидин Я.А., Скуркович С.В., Скурко- вич Б.С. Новые направления в антицигокиновон терапии ревматоидного артрита (первьш опыт использования антиинтерферонов). Клин, ревматол,. 1997, 3.9-16.</p><p>Лукина Г.В., Сигидин Я.А. Скуркович С.В., Скуркович Б.С. Новые подходы к биологической иммуно- модулирующен терапии ревматоидного артрита: нейтрализация основных цитокинов. Тер. архив. 1998, 5, 32-37.</p><p>Сигидин Я.А., Лукина Г.В., Гусев Д.Е. О базисных свойствах глюкокортнкостероидов при ревматоидном артрите. Клин, фармакол. и тер., 2000, 1, 55-57.</p><p>Сигидин Я.А., Лукина Г.В. Базисная (патогенетическая) терапия ревматоидного артрита, М. 2000, 100.</p><p>Beighton R., Solomon L., Valkenburg H.A. Rheumatoid arthritis in a rural Soulh African Negro population. Ann.Rheum.Dis., 1975, 34, 136.</p><p>Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann. Rheum. Dis. 1999, 58, suppl. 1, 96-98.</p><p>Cutolo М., Straub R.H. Recent aspects of gonadal hormone and neurotransmitter interactions with synovial and immune cells: implications in rheumatoid arthritis. Ann. Rheum. Dis., 2000, 59, 657-661.</p><p>Elliott M.J., Maini R.N., Feldmann M. el al. Randomised double blind comparison of a chimaeric monoclonal antibody to tumor necrosis factor alfa (cA2) versus placebo in rheumatoid arthritis. Lancet, 1994, 344, 11051110.</p><p>Felder М., Ruegsegger P, Bone loss in patients with rheumatoid arthritis. Rheumatol. Internal., 1991, 11, 41-44.</p><p>Ferrara N. Molecular aand biological properties of vascular endothelial growth factor. J, Molec. Med., 1999, 77, 527-543.</p><p>Garrison L., McDonnell N.D. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis., 1999, 5S, suppl. 1, 165-169.</p><p>Gough A., Lilley J., Eyre S. et al. Generalised bone loss in patients with early rheumatoid arthritis occurs early and relates to disease activity. Lancet, 1994, 344, 23-27.</p><p>Harriman G., Harper L.K. Schaible T.F. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF alfa treatment. Ann. Rheum. Dis., 1999, 58, suppl. 1, 61-64.</p><p>Kirwan J.B. and ARC Low Dose Corticosteroid Group. Radiological progression in rheumatoid arthritis during a randomised controlled trial of prednisolone. Rheumatol. in Europe, 1995, 24, suppl. 3, 223.</p><p>Koch A.E. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann. Rheum. Dis., 2000, 59, suppl. 1, 65-71.</p><p>Leboff M.S., Wade J., Mackowiak S. et al. Low doses prednisone does not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis. J. Rheumatol., 1991. 18, 339-344.</p><p>Lipsky P.E. Rheumatoid arthritis: new approaches for the new century. Ann. Rheum. Dis., 2000,59, suppl. 1, 5.</p><p>Maini R.N., Breedveld F.C., Kalden J.R. et al. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor alfa monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthr. Rheum., 1998, 41, 1552-1563.</p><p>Moscow J.A., Cowan K.H. Multidrug resistance. J.Natl. Cancer Inst., 1988,80, 14-20.</p><p>Nepom G.T. HLA-DR4 and rheumatoid arthritis. In: Wolfe F., Pincus T. teds). Rheumatoid arthritis. Marcel Dekker, Inc; NY-Basel-Hong Kong, 1994, 115-129.</p><p>Paulus H.E. Machleder H.J., Peter J.B. Clinical improvement of rheumatoid arthritis during prolonged thoracic duct lymphocyte drainage. Arthr. Rheum., 1973, 16, 562.</p><p>Pearson C.M. Transfer of adjuvant arthritis by means of lymph node or spleen cells. J. Belg. Rheumatol. Med. Phys. 1969.24, 150.</p><p>Sekine Т., Masuko-Hongo K., Matsui T. et al. Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann, Rheum. Dis., 2001, 60, 49-54.</p><p>Solomon L., Robin C., Valkenburg H.A. Rheumatoid arthritis in an urban South African Negro population, Ann. Rheum. Dis., 1975, 34, 128.</p><p>Verstraeten A„ Dequecker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis. Ann. Rheum. Dis., 1986, 45, 852-S57.</p><p>Wegelius O., Laire W., Lindstrom B„ Klockars M. Fistula of thoracic duct as immunosuppressive treatment in rheumatoid arthritis. Acta Med, Scand., 1970, 187, 539.</p><p>Whitehouse M.W., Whitehouse D.J., Pearson C.M. Passive transfer of adjuvant-induced arthritis and allergic encephalomyelitis in rats using thoracic duct lymphocytes. Nature, 1969, 224, 1322.</p><p>Yarbo J,W. The scientific basis of cancer chemotherapy. In: Perry M.C. (ed.) The chemotherapy source book, 2nd ed, Williams & Wilkins. Baltimore, 1996, 3-18.</p></div><br /><div><p>Гусев Д.Е. Влияние глюкокортикостероидов на прогрессирование ревматоидного артрита. Автореферат канд. дисс. М., 1997,29.</p><p>Гусев Д.Е. Сигидин Я.А. К характеристике влияния кортикостероидов на деструкцию суставов при ревматоидном артрите. Клин, ревматол., 1996. 1, 29-32.</p><p>Лукина Г.В., Сигидин Я.А., Скуркович С.В., Скурко- вич Б.С. Новые направления в антицигокиновон терапии ревматоидного артрита (первьш опыт использования антиинтерферонов). Клин, ревматол,. 1997, 3.9-16.</p><p>Лукина Г.В., Сигидин Я.А. Скуркович С.В., Скуркович Б.С. Новые подходы к биологической иммуно- модулирующен терапии ревматоидного артрита: нейтрализация основных цитокинов. Тер. архив. 1998, 5, 32-37.</p><p>Сигидин Я.А., Лукина Г.В., Гусев Д.Е. О базисных свойствах глюкокортнкостероидов при ревматоидном артрите. Клин, фармакол. и тер., 2000, 1, 55-57.</p><p>Сигидин Я.А., Лукина Г.В. Базисная (патогенетическая) терапия ревматоидного артрита, М. 2000, 100.</p><p>Beighton R., Solomon L., Valkenburg H.A. Rheumatoid arthritis in a rural Soulh African Negro population. Ann.Rheum.Dis., 1975, 34, 136.</p><p>Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann. Rheum. Dis. 1999, 58, suppl. 1, 96-98.</p><p>Cutolo М., Straub R.H. Recent aspects of gonadal hormone and neurotransmitter interactions with synovial and immune cells: implications in rheumatoid arthritis. Ann. Rheum. Dis., 2000, 59, 657-661.</p><p>Elliott M.J., Maini R.N., Feldmann M. el al. Randomised double blind comparison of a chimaeric monoclonal antibody to tumor necrosis factor alfa (cA2) versus placebo in rheumatoid arthritis. Lancet, 1994, 344, 11051110.</p><p>Felder М., Ruegsegger P, Bone loss in patients with rheumatoid arthritis. Rheumatol. Internal., 1991, 11, 41-44.</p><p>Ferrara N. Molecular aand biological properties of vascular endothelial growth factor. J, Molec. Med., 1999, 77, 527-543.</p><p>Garrison L., McDonnell N.D. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis., 1999, 5S, suppl. 1, 165-169.</p><p>Gough A., Lilley J., Eyre S. et al. Generalised bone loss in patients with early rheumatoid arthritis occurs early and relates to disease activity. Lancet, 1994, 344, 23-27.</p><p>Harriman G., Harper L.K. Schaible T.F. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF alfa treatment. Ann. Rheum. Dis., 1999, 58, suppl. 1, 61-64.</p><p>Kirwan J.B. and ARC Low Dose Corticosteroid Group. Radiological progression in rheumatoid arthritis during a randomised controlled trial of prednisolone. Rheumatol. in Europe, 1995, 24, suppl. 3, 223.</p><p>Koch A.E. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann. Rheum. Dis., 2000, 59, suppl. 1, 65-71.</p><p>Leboff M.S., Wade J., Mackowiak S. et al. Low doses prednisone does not affect calcium homeostasis or bone density in postmenopausal women with rheumatoid arthritis. J. Rheumatol., 1991. 18, 339-344.</p><p>Lipsky P.E. Rheumatoid arthritis: new approaches for the new century. Ann. Rheum. Dis., 2000,59, suppl. 1, 5.</p><p>Maini R.N., Breedveld F.C., Kalden J.R. et al. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor alfa monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthr. Rheum., 1998, 41, 1552-1563.</p><p>Moscow J.A., Cowan K.H. Multidrug resistance. J.Natl. Cancer Inst., 1988,80, 14-20.</p><p>Nepom G.T. HLA-DR4 and rheumatoid arthritis. In: Wolfe F., Pincus T. teds). Rheumatoid arthritis. Marcel Dekker, Inc; NY-Basel-Hong Kong, 1994, 115-129.</p><p>Paulus H.E. Machleder H.J., Peter J.B. Clinical improvement of rheumatoid arthritis during prolonged thoracic duct lymphocyte drainage. Arthr. Rheum., 1973, 16, 562.</p><p>Pearson C.M. Transfer of adjuvant arthritis by means of lymph node or spleen cells. J. Belg. Rheumatol. Med. Phys. 1969.24, 150.</p><p>Sekine Т., Masuko-Hongo K., Matsui T. et al. Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann, Rheum. Dis., 2001, 60, 49-54.</p><p>Solomon L., Robin C., Valkenburg H.A. Rheumatoid arthritis in an urban South African Negro population, Ann. Rheum. Dis., 1975, 34, 128.</p><p>Verstraeten A„ Dequecker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis. Ann. Rheum. Dis., 1986, 45, 852-S57.</p><p>Wegelius O., Laire W., Lindstrom B„ Klockars M. Fistula of thoracic duct as immunosuppressive treatment in rheumatoid arthritis. Acta Med, Scand., 1970, 187, 539.</p><p>Whitehouse M.W., Whitehouse D.J., Pearson C.M. Passive transfer of adjuvant-induced arthritis and allergic encephalomyelitis in rats using thoracic duct lymphocytes. Nature, 1969, 224, 1322.</p><p>Yarbo J,W. The scientific basis of cancer chemotherapy. In: Perry M.C. (ed.) The chemotherapy source book, 2nd ed, Williams & Wilkins. Baltimore, 1996, 3-18.</p></div><br />
The authors declare that there are no conflicts of interest present.